LONG MINI-FUTURE - GENMAB | Market Closed - Börse Stuttgart 02:24:35 2024-06-14 EDT | ||
| 11.36 EUR | -1.22% |
|
| Current month | -10.97% | ||
| 1 month | -18.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 11.36 | -1.22% |
| 24-06-13 | 11.5 | -7.18% |
| 24-06-12 | 12.39 | -3.50% |
| 24-06-11 | 12.84 | -1.76% |
| 24-06-10 | 13.07 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 02:24 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA8X42 |
| ISIN | DE000VA8X421 |
| Date issued | 2018-10-29 |
| Strike | 963 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.89 € |
|---|---|
| Lowest since issue | 1.54 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat
